Navigation Links
VIVUS to Present at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

MOUNTAIN VIEW, Calif., March 29, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual Needham Healthcare Conference.  

The VIVUS presentation will take place at the Palace Hotel in New York, New York on Tuesday, April 5, 2011 at 2:00 p.m. ET.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com. CONTACT:   VIVUS, Inc.Investor Relations: The Trout GroupTimothy E. Morris

Brian KorbChief Financial Officer

bkorb@troutgroup.com650-934-5200

646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
2. VIVUS to Present at Four Upcoming Investor Conferences
3. VIVUS to Present at Two Upcoming Investor Conferences
4. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
5. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
6. VIVUS to Present at Four Upcoming Healthcare Conferences
7. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
8. VIVUS to Present at the Needham and Company Life Sciences Conference
9. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
10. VIVUS Reports First Quarter 2009 Financial Results and Highlights
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):